Volume 86 Issue 12 | p. 17 | Concentrates
Issue Date: March 24, 2008

Nuvelo Restructures After Trial Fails

Department: Business

Nuvelo is overhauling its operations after its lead drug candidate, alfimeprase, did not prove more effective in restoring catheter function than the gold-standard product, Genentech's Cathflo Activase. Roughly 40 employees, including Michael D. Levy, executive vice president of R&D, will be let go. Nuvelo says it will cease development of alfimeprase, an enzyme that was also being developed to treat acute ischemic stroke.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment